Search
for

    GlossaryNilotinib

    medication treats certain leukemias by inhibiting cancer-promoting proteins

    Nilotinib is a medication used to treat certain types of leukemia, specifically chronic myeloid leukemia (CML). It works by inhibiting the activity of a protein called BCR-ABL, which is produced by cancer cells and promotes their growth. By blocking this protein, Nilotinib helps to slow down or stop the progression of the disease.

    Related Terms

    Sort by

    Community Join

    30 / 1000+ results

      community Can scalp buildup Cause hair loss?

      in Chat  8 upvotes 1 year ago
      The user is experiencing severe hair shedding while on finasteride and plans to start using ketoconazole shampoo to address a greasy, waxy scalp buildup. They are seeking additional advice for managing hair loss.

      community Carnitine Tartrate + Potassium chloride + Niacin

       10 upvotes 11 years ago
      The post discusses using Carnitine Tartrate, Potassium Chloride, and Niacin to reduce hair shedding, with the user experiencing significant improvement. The user also suggests considering a ketogenic/paleo diet for those with insulin resistance-related hair loss.

      community Kintor pyrilutamide presentation?

      in Research/Science  12 upvotes 3 years ago
      The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.

      community Kintor develop GT20026 Anti-Androgen receptor drug with NO SIDES

      in Treatment  17 upvotes 5 years ago
      The conversation discusses GT20029, a new topical drug for hair loss and acne without notable side effects, which has been accepted for investigational use in China. Some users express skepticism about the legitimacy of the company and the potential for other drugs like RU58841 to be developed due to patent expiration and lack of profitability.

      community Kintor Phase 2 Results released KX-826 (pyrilutamide)

      in Research/Science  447 upvotes 3 years ago
      Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.

      community Pyrilutamide cease and desist from Kintor

      in Transplants  12 upvotes 3 years ago
      Considering a hair transplant, using Pyrilutamide, the potential availability of CosmeRNA, and the significance of taking Minoxidil and Finasteride for long-term results.

      community Anagenic is trying to compound Gt20029

      in Treatment  58 upvotes 3 years ago
      The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

      community Ruxolitinib - Start of a case study

      in Research/Science  10 upvotes 1 year ago
      The conversation is about a user trying a new hair loss treatment, Ruxolitinib, alongside their existing regimen of finasteride, minoxidil, ketoconazole shampoo, and microneedling. They plan to apply Ruxolitinib to their temples daily for 1-2 months.

      community Pyrilutamide kintor pharmaceutical

      in Chat  6 upvotes 2 years ago
      The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.

      community pyrilutamide solution progress log

      in Product  20 upvotes 3 years ago
      A 28 year old using a hair loss prevention protocol to restore thinning hair, which includes finasteride, dutasteride, minoxidil, stemoxydine, alopecin, nizoral shampoo and microneedling; the user is now adding pyrilutamide solution to the regimen with the hope of improving their results. RU58841 was also ordered but not yet used.

      community GT20029. Kintor Pharma’s Product

      in Research/Science  12 upvotes 3 years ago
      The conversation discusses GT20029, a compound by Kintor Pharma that degrades androgen receptors and is in trials, with potential as a hair loss cure. Another promising treatment mentioned is an antibody that blocks prolactin and has shown positive results in macaques.

      community Pyrilutamide isn’t failed at all.

      in Technology  11 upvotes 1 year ago
      Kintor is producing a cosmetic with KX826, starting at 0.5% concentration and moving to 1%. The 0.5% concentration wasn't as effective as minoxidil and finasteride, but the 1% concentration shows promise.

      community Pyrilutamide US Phase 2 Trial?

      in Research/Science  27 upvotes 3 years ago
      The Phase 2 trial for Pyrilutamide in the US, which started a year after the China trials, and inquiring about any available information on when it will finish. Treatments discussed include Minoxidil, Finasteride, and RU58841.

      community Kintor long term safety phase 3

      in Research/Science  66 upvotes 1 year ago
      Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.

      community Anyone immediately lose hope for gt20029 when they realised it’s developed by kintor

      in Research/Science  6 upvotes 3 months ago
      The conversation discusses various hair loss treatments, including minoxidil, finasteride, dutasteride, pyrilutamide, alfatrodial, and nizoral, with a focus on the potential of new treatments like gt20029 and breezula. There is optimism about novel treatments that don't have systemic effects, although skepticism remains about the effectiveness of some new drugs.
    Next page →